



UNITED STATES PATENT AND TRADEMARK OFFICE

ST

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/677,956	10/01/2003	Suzanne Zebedec	323-100US D	9260

7590 02/22/2006

Joseph E. Mueth, Esq.
Joseph E. Mueth Law Corporation
8th Floor
225 South Lake Avenue
Pasadena, CA 91101

EXAMINER

LUCAS, ZACHARIAH

ART UNIT

PAPER NUMBER

1648

DATE MAILED: 02/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claim 77, drawn to an HCV capsid antigen, classified in class 424, subclass 228.1.
 - II. Claims 78-80, drawn to assays for detecting anti-HCV capsid antibodies in a sample, classified in class 435, subclass 7.1.
 - III. Claims 81-84, drawn to an expression vector encoding an HCV non-structural 794 antigen, classified in class 536, subclass 23.72.
 - IV. Claim 85, drawn to a method to produce an HCV nonstructural 764 antigen, classified in class 435, subclass 69.3.
 - V. Claim 86-88, drawn to an HCV nonstructural 764 antigen, classified in class 424, subclass 228.1.
 - VI. Claim 89-91, drawn to assays for detecting anti-HCV non-structural 794 antibodies in a sample, classified in class 435, subclass 7.1.
 - VII. Claims 92-98, drawn to compositions comprising HCV capsid and non-structural 794 antigens, classified in class 435, subclass 228.1.
 - VIII. Claims 99-101, drawn to assays for detecting anti-HCV capsid and anti-HCV non-structural 794 antibodies in a sample, classified in class 435, subclass 7.1.

The inventions are distinct, each from the other because of the following reasons:

2. The inventions of Groups VII-VIII are related as combination and subcombinations with the inventions of both Groups I and II and Groups V and VI. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the combination may rely on either or the combination of the subcombinations for patentability. The subcombinations have the same separate utility as the combination.

3. The inventions of Groups I, V, and VI are related as product and process of use with the inventions of Groups II, VI, and VIII. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the claimed products may be used in method for the detection of antibodies as claimed, or in methods for inducing an immune response. The products are therefore distinct from the claimed methods of use.

4. Inventions of Groups I and II are unrelated to the inventions of Groups V and VI. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the inventions of Groups I and II are drawn to inventions relating to a different antigen (each of which has a different structure), or a method of using such to detect antibodies directed against the different antigens (thereby having different

Art Unit: 1648

modes of operation). Because the inventions are drawn to different compounds, or methods of using such, the two sets of inventions are distinct one from the other.

5. The inventions of Groups III and IV are unrelated to the inventions of Groups I and II. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are drawn to different types of compounds, and different methods each having a different mode of operation and a different effect. The inventions are therefore distinct.

6. The inventions of Group III are unrelated to the invention of Groups V and VII. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are drawn to different types of compounds, each of which has a different structure, and has a different function. Because these inventions have different structures and functions, and because the searches required for such different compounds are different, the inventions are distinct.

7. The inventions of Group IV and of Groups V and VII are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the antigens of Groups V and VII may be made through different processes, such as by purification or by protein synthesis. The products are therefore distinct from the methods of making.

Art Unit: 1648

8. The inventions of Groups III and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the polynucleotide of Group III may be used in the method for producing a peptide as in Group IV, or may be used in methods for detecting viral sequence in a hybridization assay. The inventions are therefore distinct.

Species Election

9. This application contains claims directed to the following patentably distinct species of the claimed invention:

If any of Groups II, VI, or VIII are elected above, the Applicant is additionally required to elect one of each from species (A)-(C), and species (1)-(5).

Species (A)-(C) represent the elected invention wherein the specific binding agent is (A) protein A, (B) and IgG antibody, or (C) and IgM antibody.

Species (1)-(3) represent the elected invention wherein the label is (1) a lanthanide chelate, (2) biotin, (3) an enzyme, (4) a radioactive isotope, or (5) a fluorescent moiety.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 78 is generic in Group II, claim 89 is generic in Group VI, and claim 99 is generic in Group VIII.

Art Unit: 1648

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

10. Because these inventions are distinct for the reasons given above, have acquired a separate status in art because of recognized divergent subject matter and different classifications, and because the literature and sequence searches required for any one of the groups is not required for the others, restriction for examination purposes as indicated is proper.

11. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend**

Art Unit: 1648

from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.


12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zachariah Lucas whose telephone number is 571-272-0905. The examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Z. Lucas
Patent Examiner


JAMES HOUSEL
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600
2/29/06